Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers

[Guest guest]

Hepatogastroenterology. 2003 Nov-Dec;50(54):2154-6.

Limited value of 18F-2-deoxyglucose positron emission tomography to detect

hepatocellular carcinoma in hepatitis B virus carriers.

Jeng LB, Changlai SP, Shen YY, Lin CC, Tsai CH, Kao CH.

Department of Surgery, China Medical University Hospital, No. 2, Yuh-Der

Road, Taichung 404, Taiwan.

BACKGROUND/AIMS: The differentiation of hepatocellular carcinoma from benign

liver diseases in hepatitis B virus carriers by imaging studies based upon

morphological aspects can be difficult. METHODOLOGY: FDG-PET

(18F-2-deoxyglucose positron emission tomographies) were performed in 48

hepatitis B virus carriers to detect hepatocellular carcinoma and

differentiate other benign liver diseases. In each patient, the focal liver

lesion was visible by ultrasound and an elevated serum alpha-fetoprotein

level was noted. Definite diagnosis was established after ultrasound-guided

liver biopsy followed by histopathological examination. RESULTS: The

histopathological examination revealed hepatocellular carcinoma in 36

patients and benign liver diseases in the remaining 12 patients. Twenty of

36 hepatocellular carcinomas were detectable by FDG-PET and none of 12

benign liver diseases were visualized by FDG-PET. The detection sensitivity

of FDG-PET was not related to the echogenicity and size of hepatocellular

carcinoma. CONCLUSIONS: FDG-PET is not sensitive to but is more specific

than ultrasound and serum alpha-feto-protein level to detect hepatocellular

carcinoma and differentiate from other benign liver diseases in hepatitis B

virus carriers.

PMID: 14696485 [PubMed - in process]

[Guest guest]

Hepatogastroenterology. 2003 Nov-Dec;50(54):2154-6.

Limited value of 18F-2-deoxyglucose positron emission tomography to detect

hepatocellular carcinoma in hepatitis B virus carriers.

Jeng LB, Changlai SP, Shen YY, Lin CC, Tsai CH, Kao CH.

Department of Surgery, China Medical University Hospital, No. 2, Yuh-Der

Road, Taichung 404, Taiwan.

BACKGROUND/AIMS: The differentiation of hepatocellular carcinoma from benign

liver diseases in hepatitis B virus carriers by imaging studies based upon

morphological aspects can be difficult. METHODOLOGY: FDG-PET

(18F-2-deoxyglucose positron emission tomographies) were performed in 48

hepatitis B virus carriers to detect hepatocellular carcinoma and

differentiate other benign liver diseases. In each patient, the focal liver

lesion was visible by ultrasound and an elevated serum alpha-fetoprotein

level was noted. Definite diagnosis was established after ultrasound-guided

liver biopsy followed by histopathological examination. RESULTS: The

histopathological examination revealed hepatocellular carcinoma in 36

patients and benign liver diseases in the remaining 12 patients. Twenty of

36 hepatocellular carcinomas were detectable by FDG-PET and none of 12

benign liver diseases were visualized by FDG-PET. The detection sensitivity

of FDG-PET was not related to the echogenicity and size of hepatocellular

carcinoma. CONCLUSIONS: FDG-PET is not sensitive to but is more specific

than ultrasound and serum alpha-feto-protein level to detect hepatocellular

carcinoma and differentiate from other benign liver diseases in hepatitis B

virus carriers.

PMID: 14696485 [PubMed - in process]

[Guest guest]

Hepatogastroenterology. 2003 Nov-Dec;50(54):2154-6.

Limited value of 18F-2-deoxyglucose positron emission tomography to detect

hepatocellular carcinoma in hepatitis B virus carriers.

Jeng LB, Changlai SP, Shen YY, Lin CC, Tsai CH, Kao CH.

Department of Surgery, China Medical University Hospital, No. 2, Yuh-Der

Road, Taichung 404, Taiwan.

BACKGROUND/AIMS: The differentiation of hepatocellular carcinoma from benign

liver diseases in hepatitis B virus carriers by imaging studies based upon

morphological aspects can be difficult. METHODOLOGY: FDG-PET

(18F-2-deoxyglucose positron emission tomographies) were performed in 48

hepatitis B virus carriers to detect hepatocellular carcinoma and

differentiate other benign liver diseases. In each patient, the focal liver

lesion was visible by ultrasound and an elevated serum alpha-fetoprotein

level was noted. Definite diagnosis was established after ultrasound-guided

liver biopsy followed by histopathological examination. RESULTS: The

histopathological examination revealed hepatocellular carcinoma in 36

patients and benign liver diseases in the remaining 12 patients. Twenty of

36 hepatocellular carcinomas were detectable by FDG-PET and none of 12

benign liver diseases were visualized by FDG-PET. The detection sensitivity

of FDG-PET was not related to the echogenicity and size of hepatocellular

carcinoma. CONCLUSIONS: FDG-PET is not sensitive to but is more specific

than ultrasound and serum alpha-feto-protein level to detect hepatocellular

carcinoma and differentiate from other benign liver diseases in hepatitis B

virus carriers.

PMID: 14696485 [PubMed - in process]

[Guest guest]

Hepatogastroenterology. 2003 Nov-Dec;50(54):2154-6.

Limited value of 18F-2-deoxyglucose positron emission tomography to detect

hepatocellular carcinoma in hepatitis B virus carriers.

Jeng LB, Changlai SP, Shen YY, Lin CC, Tsai CH, Kao CH.

Department of Surgery, China Medical University Hospital, No. 2, Yuh-Der

Road, Taichung 404, Taiwan.

BACKGROUND/AIMS: The differentiation of hepatocellular carcinoma from benign

liver diseases in hepatitis B virus carriers by imaging studies based upon

morphological aspects can be difficult. METHODOLOGY: FDG-PET

(18F-2-deoxyglucose positron emission tomographies) were performed in 48

hepatitis B virus carriers to detect hepatocellular carcinoma and

differentiate other benign liver diseases. In each patient, the focal liver

lesion was visible by ultrasound and an elevated serum alpha-fetoprotein

level was noted. Definite diagnosis was established after ultrasound-guided

liver biopsy followed by histopathological examination. RESULTS: The

histopathological examination revealed hepatocellular carcinoma in 36

patients and benign liver diseases in the remaining 12 patients. Twenty of

36 hepatocellular carcinomas were detectable by FDG-PET and none of 12

benign liver diseases were visualized by FDG-PET. The detection sensitivity

of FDG-PET was not related to the echogenicity and size of hepatocellular

carcinoma. CONCLUSIONS: FDG-PET is not sensitive to but is more specific

than ultrasound and serum alpha-feto-protein level to detect hepatocellular

carcinoma and differentiate from other benign liver diseases in hepatitis B

virus carriers.

PMID: 14696485 [PubMed - in process]